Hints and tips:
...“It’s a Cinderella story,” said Stacey Schultz-Cherry, an infectious disease specialist at St Jude’s Children’s Research Hospital in Tennessee....
...While at St Jude, he established a vaccine study centre in the Eastern Highlands of Zimbabwe with Africa University....
...US pharmaceutical Abbott Laboratories also on Thursday announced a $25bn deal for St Jude Medical, while France’s Sanofi earlier today went public with the details of an unsolicited bid for San Francisco-based...
...So we’ll also keep an eye on St Jude Medical’s defamation lawsuit in Minnesota against Muddy Waters and MedSec Holdings, after their report claiming its pacemaker devices were unsafe earlier this year....
...Abbott Healthcare, which AbbVie was spun out of in 2013, said it would buy St Jude, a medical device group, for $25bn, while France’s Sanofi launched an unsolicited $9.3bn bid for San Francisco-based Medivation...
...Elsewhere, St Jude Medical, a maker of devices for the heart-care industry, surged by 25.5 per cent to $77.78 after Abbott Laboratories said it agreed to buy the group for $25bn....
...St Jude Medical shares fell 1.7 per cent to $41.21 after the stock’s rating was cut to “underperform” by RBC capital....
...Jude Medical Cardiac Rhythm Management Division (“St. Jude”). AorTech and its subsidiaries have served on St Jude a Rectification Notice, which asserts material breaches by St....
...Rival St Jude Medical rose 3.2 per cent to $35.70 after it said it still expected to meet fourth-quarter and full-year guidance....
...Device manufacturer St Jude Medical tumbled 7 per cent, to end the week up 3 per cent to $35.83....
...All these companies offer newer, fast-growing products, but few of these are likely to be as large as those that are struggling: Bernstein Research pegs global annual sales of pacemakers and defibrillators...
...St Jude Medical , the medical device maker, rose 1.9 per cent to $41.73 after the company said it expected its fourth-quarter earnings figures to be at the top end of its previous estimates of between 72...
...St Jude Medical jumped 5.6 per cent to $36.95 after the medical device maker said fourth quarter earnings would beat forecasts....
...St Jude Medical was more fortunate, jumping 8.9 per cent over the week to $38.43, after two of its implantable heart devices were approved by European regulators....
...St Jude Medical sank 10.1 per cent to $33.63, and Boston Scientific lost 8.9 per cent to $15.95. Sprint Nextel tumbled 14.5 per cent to $17.54, its worst week since July 2002....
...Talk turned to whether J&J would pursue alternative targets, with St Jude Medical and ImClone the names in the frame....
...St Jude jumped 4.7 per cent to $50.56 on speculation that the company might become a bid target for the loser of the Guidant deal....
...But St Jude Medical gained 6.3 per cent to $51.32 on the week following speculation that the company might become an acquisition target for the loser of the Guidant deal....
...A trio of US companies, Medtronic, Guidant and St Jude, dominate the global market for implantable heart rhythm devices....
...In medical devices, it could pursue St Jude. In pharmaceuticals, it is considering a purchase of Serono....
International Edition